MarketBeat provided average ratings and consensus target prices for Pacira BioSciences, while Needham and Royal Bank of Canada issued rating updates.
3 reports, 1 independent
Updated Fri 00:00
No new developments lately
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat provided average ratings and consensus target prices for Pacira BioSciences, while Needham and Royal Bank of Canada issued rating updates.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Needham & Company
American independent investment bank and asset management firm
-
Royal Bank of Canada
financial institution in Canada
Related events
- MarketBeat reports average rating and target price for SS&C Technologies, while RBC boosts targets and Jefferies reduces its price objective.
- Needham & Company downgraded Heron Therapeutics stock rating, while MarketBeat provided average stock rating data.
- MarketBeat reports consensus ratings from sixteen brokerages, including RBC's 'outperform' rating and Scotiabank's target price cut for Lightspeed.
- RBC invested in BOSC shares, and MarketBeat provided a consensus rating for the company.
- Royal Bank of Canada provided a sector perform rating for Helmerich & Payne, with MarketBeat aggregating average stock rating data.